Dual Agonist Peptide Composition for Weekly Dosing Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for obesity and diabetes, such as GLP-1 and glucagon dual agonists, require chronic self-medication, posing challenges in patient compliance and quality of life.
Innovation Solution
Development of GLP-1 and glucagon dual agonist peptides with improved biological stability and duration of action, allowing for weekly administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current GLP-1 and glucagon therapies are used, then glycemic control and weight loss effects are achieved, but chronic self-medication and frequent dosing requirements increase patient burden and reduce compliance
Solution Approach 1:
The patent modifies the chemical structure of dual agonist peptides by changing parameters such as amino acid sequences, adding modifications at specific positions (e.g., position 10, 13, 17, 20, or 24), and adjusting molecular properties to extend half-life and reduce dosing frequency while maintaining therapeutic efficacy
Solution Approach 2:
The invention creates composite peptide structures combining GLP-1 and glucagon functional domains within a single molecular sequence, allowing one peptide to simultaneously activate both receptor pathways, thereby reducing the need for multiple separate administrations
2Duration of action of moving object
If dual agonist peptides are designed with extended half-life, then dosing frequency is reduced and patient compliance improves, but proteolytic stability must be enhanced to maintain duration of action
Solution Approach 1:
The patent systematically modifies peptide parameters including amino acid substitutions, adding cyclization, and incorporating modifications at specific positions to simultaneously extend half-life and enhance proteolytic stability, ensuring the peptide maintains both prolonged duration of action and resistance to enzymatic degradation
Data Source
AI summary
GLP-1 and glucagon dual agonists disclosed herein have improved biological stability, including proteolytic stability, and duration of action. The peptides can be administered about once a week.